This is an open-label, non-controlled, non-randomized study to investigate the long-lasting
radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluation
safety and dosimetry of 177Lu-DOTA-EB-TATE in patients with advanced metastatic
neuroendocrine tumors. A single dose of 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE
will be injected intravenously. and monitored at 2, 24, 72,120 and 168 hours post-injection
with semiquantitative method based on quantitative single-photon emission computed
tomography/computed tomography (SPECT/CT) performance.